Citi is out with its report today on United Therapeutics UTHR, upgrading UTHR from Neutral to Add.
In a note to clients, Citi writes, "We are upgrading UTHR to Add (from Neutral) and raising our 12-month price target to $70 (from $65) based on our expectations for a positive outcome from the FREEDOM-M trial testing oral treprostinil in Pulmonary Arterial Hypertension. We anticipate top-line data for FREEDOM-M in mid-June, and we expect details including average dose at 12 weeks, drop-out rate, and clinical worsening to also be presented. Although the upside/downside risk looks challenging, we believe FREEDOM-M will ultimately be successful, resulting in upside potential to the current share price."
Shares of UTHR closed Thursday at $65.27, down 0.37% from Wednesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorUpgradesPrice TargetAnalyst RatingsBiotechnologyCitiHealth Careunited therapeutics
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in